# DNA Script

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dna-script

- Industry: Biotechnology
- Headquarters: France
- Website: www.dnascript.com
- Total disclosed funding: $327M
- Latest round: Series C (Jan 4, 2022)
- Investors on record: 26

## About

Based in Le Kremlin-Bicêtre, France, and founded in 2014 by Sylvain Gariel, Thomas Ybert, and Xavier Godron, DNA Script Inc. develops and provides template-free enzymatic technology for synthetic DNA (Deoxyribonucleic acid) production. In October 2021, DNA Script SAS raised USD 165 million in a Series C funding co-led by Catalio Capital Management, Coatue Management with participation from ArrowMark Partners, Columbia Threadneedle Investments, Farallon Capital Management, Fidelity Investments, Moore Strategic Ventures, Alexandria Venture Investments, Agilent Technologies, Bpifrance Investissement, Casdin Capital, Danaher Corporation, Illumina Ventures, Kurma Partners, Life Sciences Partners, and M Ventures. DNA Script SAS has raised a total of USD 297.87 million in funding and co-founder Thomas Ybert is its CEO.

DNA Script SAS’s product line includes the Syntax system, Syntax 60-cycle kit, 96 oligos, and Syntax software suite. The Syntax system is powered by Enzymatic DNA Synthesis (EDS) technology is a DNA printer that enables the on-demand synthesis of custom DNA oligos in a benchtop solution. Syntax 60-cycle kit, 96 oligos is also powered with EDS technology for template-free synthesis. The Syntax software suite is an intuitive, remote interface for seamless planning and automation. DNA Script has developed an alternative to traditional DNA synthesis, which is Enzymatic DNA Synthesis (EDS) that allows technology to be feasible for the labs with the Syntax System.

The company has generated a revenue of USD 1.009 million in the financial year 2019 and for 2018, the revenue was USD 0.01 million. 

DNA Script plans to use its proceeds from a Series C funding to accelerate the expansion and commercialization of its SYNTAX Platform and broaden its portfolio of products powered by EDS.

## Funding rounds

- Series C, Jan 4, 2022, $34M — T Rowe Price, EQT Life Sciences, Alexandria Venture Investments, Columbia Threadneedle Investments, Agilent Technologies, Bpifrance Investissement Régions, Fidelity Investments, Danaher Corporation, Kurma Partners, Coatue Management, HealthCor Group, ArrowMark Partners, Casdin Capital, Farallon Capital Management, Illumina Ventures, M Ventures, Moore Strategic Ventures, Baillie Gifford, Irving Investors, Catalio Capital Management, EureKARE SA
- Series C, Oct 26, 2021, $165M — EQT Life Sciences, Alexandria Venture Investments, Agilent Technologies, Fidelity Investments, Danaher Corporation, Kurma Partners, Coatue Management, ArrowMark Partners, Casdin Capital, Farallon Capital Management, Bpifrance Investissement, Illumina Ventures, M Ventures, Moore Strategic Ventures, Columbia Threadneedle Investments, Catalio Capital Management
- Series B, Jul 29, 2020, $50M — EQT Life Sciences, Bpifrance, Danaher Corporation, Agilent Technologies Inc., Casdin Capital, Illumina Ventures, M Ventures
- Series B, Jun 5, 2019, $65M — Sofinnova Partners, Idinvest Partners, EQT Life Sciences, Bpifrance, M Ventures, Kurma Partners, Illumina Ventures
- Series A, Aug 17, 2017, $13M — Sofinnova Partners, Idinvest Partners, M Ventures, Kurma Partners, Illumina Ventures

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A, Series B
- Idinvest Partners (https://capitalatlas.ai/funds/idinvest-partners) — Series A, Series B
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Series A, Series B, Series C
- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Series A, Series B, Series C
- Illumina Ventures (https://capitalatlas.ai/funds/illumina-ventures) — Series A, Series B, Series C
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series B, Series C
- Bpifrance — Series B
- Danaher Corporation — Series B, Series C
- Agilent Technologies Inc. — Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B, Series C
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series C
- Agilent Technologies — Series C
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series C
- Coatue Management (https://capitalatlas.ai/funds/coatue-management) — Series C
- ArrowMark Partners — Series C
- Farallon Capital Management (https://capitalatlas.ai/funds/farallon-capital-management) — Series C
- Bpifrance Investissement (https://capitalatlas.ai/funds/bpifrance-investissement) — Series C
- Moore Strategic Ventures (https://capitalatlas.ai/funds/moore-strategic-ventures) — Series C
- Columbia Threadneedle Investments — Series C
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series C
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series C
- Bpifrance Investissement Régions (https://capitalatlas.ai/funds/bpifrance-investissement-regions) — Series C
- HealthCor Group (https://capitalatlas.ai/funds/healthcor-group) — Series C
- Baillie Gifford (https://capitalatlas.ai/funds/baillie-gifford) — Series C
- Irving Investors (https://capitalatlas.ai/funds/irving-investors) — Series C
- EureKARE SA — Series C